I'm grinning...with everyone else here
Looks like a number of interested parties, whether retail or institutional, read with interest and understanding some of the postings I put a few days ago, telling (again) some of the unique, powerful Anavex science story lines. But, those are not just a story. Reality
Which fits, now, with the SAVA stuff. But, a close read and understanding of both mechanisms of action (MOAs) show that blarcamesine is much better, has multiple applications and therapeutic outcomes, compared to competitor's drug.
SAVA entered, is in the game, now (with their clinical results). AVXL, however, is the far stronger player; will rack up lots of points; will win the game --- perhaps on a TKO (technical, meaning real technology that works, knockout).